Journal article

Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection

KA Bond, E Williams, S Nicholson, S Lim, D Johnson, B Cox, M Putland, E Gardiner, E Tippett, M Graham, F Mordant, M Catton, SR Lewin, K Subbarao, BP Howden, DA Williamson

PATHOLOGY | ELSEVIER | Published : 2021


Serological assays for SARS-CoV-2 infection are now widely available for use in diagnostic laboratories. Limited data are available on the performance characteristics in different settings, and at time periods remote from the initial infection. Validation of the Abbott (Architect SARS-CoV-2 IgG), DiaSorin (Liaison SARS-CoV-2 S1/S2 IgG) and Roche (Cobas Elecsys Anti-SARS-CoV-2) assays was undertaken utilising 217 serum samples from 131 participants up to 7 months following COVID-19 infection. The Abbott and DiaSorin assays were implemented into routine laboratory workflow, with outcomes reported for 2764 clinical specimens. Sensitivity and specificity were concordant with the range reported b..

View full abstract


Awarded by National Health and Medical Research Council (NHMRC) of Australia

Awarded by NHMRC

Funding Acknowledgements

DAW and KS are supported by Investigator Grants from the National Health and Medical Research Council (NHMRC) of Australia (APP1174555 and APP1177174, respectively) . BPH is supported by a NHMRC Practitioner Fellowship (APP1105905) . KB is supported by an NHMRC Post-graduate Scholarship (GNT1191321) . This work was supported by a grant from the NHMRC Medical Research Future Fund (APP2002317) , the Jack Ma Foundation (KS) and the A2 Milk Company (KS) . The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. The authors state that there are no conflicts of in-terest to disclose.